Company intelligence / Profile preview

AdvanDx

Woburn, Massachusetts, United States

Ownership: Private
Employees: ~20
Development stage: Other

Overview

AdvanDx developed the first LNA-based diagnostic test (vanA/B EVIGENE) and a range of FDA-approved PNA FISH™ products for rapid pathogen and resistance gene identification, with demonstrated reductions in hospital stay and antibiotic usage in clinical settings

Therapeutic areas: Infectious Diseases
Modalities: DeviceMolecular diagnostic kit
Industry: Molecular Diagnostics

Partnerships

bioMérieux (exclusive U.S. distribution for PNA FISH™ tests)

Beyond the preview

Go deeper on AdvanDx.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AdvanDx.

Explore the full profile